Calypte gets extension from Amex

Calypte Biomedical (Lake Oswego, Oregon) reported that it has received a letter from the American Stock Exchange regarding the results of a March 13 hearing conducted before a listing qualifications panel of the Amex Committee on Securities.

The panel unanimously agreed that the Amex should not move to delist Calypte's common stock at this time and that it would allow the company until July 31 to regain compliance with the Amex's continued listing standards. If not, the exchange will move to immediately delist the company.